Summary Electrophoretic isoenzyme separation provides much more precise information than measurement of alkaline phosphatases (AP). Use 
emphasize the lack of reliability of biological tests for such diagnoses. Characterization of the isoenzymes of alkaline phosphatase (AP) is one possible means of rendering the data provided by such measurements more precise. Our study was aimed at determining whether the alpha 1 fraction of AP (al AP), also called the 'fast liver' fraction, would provide more valuable information. As in our previous work on the metastases of solid tumours (Viot et al., 1983) The al AP fraction was also searched for in 22 patients during relapse. The biological tests used were the same as those listed above. All 22 patients were investigated by ultrasound; technetium scans were obtained for only 4. Six biopsies were obtained: 4 by fine needle biopsy, 1 by laparotomy, and 1 at autopsy. This fraction was also tested for in 12 patients in complete remission for at least 6 months (status confirmed since measurement; average follow-up 8 months).
Measurement techniques
Total alkaline phosphatase were measured with an optimized technique at 25°C using a Centrifichem 400 unit. Paranitrophenyl phosphate was used as the substrate. The al AP fraction was measured using a previously described technique (Viot et al., 1983) . In brief, following deposit by a microapplicator on a cellulose acetate strip, migration is allowed to take place for 25 min at pH 8.8 under a potential difference of 150V. Phosphatase activity is revealed by alpha-naphthol phosphate. The various fractions (al AP, liver, bone, intestine) are then quantified by densitometry at 610 nm (Figure 1 ). of the isopatient with a
Results
Results are summarized in Table I (Viot et al., 1979) , a patient with large abdominal adenopathies that compressed the hilar region and caused a retention syndrome during which the al AP fraction is always found (Viot et al., 1979) , a patient whose liver parenchyma showed isolated steatosis and a patient with a microscopically normal liver parenchyma. Elimination of the alcoholic intoxication in the first patient and reduction of the size of the lymph nodes by chemotherapy in the second patient led to the disappearance of the cxl AP fraction in both cases. No statistically significant correlation was found between the histological type and the presence of al AP: this fraction was seen in 6 of the 36 type 1 or 2 patients (17%) and in 10 of the 23 type 3 or 4 patients (43%).
By contrast, if the absence (A) or presence (B) of general symptoms (unexplained fever or night sweats or weight loss of over 10% during the previous 6 months) are considered, the al AP fraction was detected for only 3 of the 44 patients (7%) classed A versus 12 of the 15 patients (80%) classed B. This correlation is statistically significant (P<0.0001).
Analysis of the liver scans obtained for 22 patients and the liver sonograms obtained for 50 patients revealed no significant correlation between the presence of axl AP and image abnormalities.
Comparison with total alkaline phosphatase The cxl AP fraction was detected in 8 of the 46 patients with a normal TAP level (<200IUl-1). Liver biopsies were performed for two of these patients: One had involvement by Hodgkin's disease and the other had lesions due to chronic alcoholic hepatitis. Conversely, this fraction was absent in 9 of the 13 patients with an elevated TAP concentration; these cases included 4 young patients (8, 9, 17 and 19 years) plus 2 elderly patients (78, 80 years) with an associated bone pathology. The increase in their bone fraction was responsible for the elevated TAP level in these patients.
In our series, the TAP did not discriminate between stages I and II and stages II and IV, or between groups with (A) or without (B) general symptoms in a significant manner, whereas the al AP fraction did (Table I) .
Correlation with liver biopsy (26 patients) The al AP fraction was detected in 3 of the 22 patients whose biopsy did not show any involvement by Hodgkin's disease. One of these patients was the one with alcoholic hepatitis, another patients had isolated steatosis, and the third patient had a normal parenchyma despite marked biological pertubations (TAP> 307 IU-1).
The al AP fraction was present in the 3 patients for whom biopsy revealed liver involvement by Hodgkin's disease, even though one patient had a normal TAP level.
Patients who relapsed The al AP fraction was detected in 20 of the 22 measurements made for patients at relapse. This frequency (90%) is markedly higher than the elevation of the TAP to a pathological level which occurred in 12 (54%) of these relapses. None of the 6 biopsies obtained for 6 of these patients with the cxl AP freaction revealed any Hodgkin's disease lesions; there was one instance of Kuppferian siderosis.
Patients in remission
The al AP fraction was never detected in any of the 12 patients in complete stable remission.
Correlation with disease evolution Forty-two patients who did not have the cxl AP fraction at the time of diagnosis achieved remission (median duration 14 months). None of these patients has relapsed, and the al AP fraction appeared only temporarily in a patient with hepatitis B.
Thirteen patients who initially exhibited the al AP fraction have achieved remission, and have not relapsed to date (median 17 months; range 7-36 months). The al AP disappeared during remission in all cases and has never reappeared since.
Three patients who initially has the oxl AP fraction did not achieve remission; the Lxl AP fraction was present at all times during disease evolution.
Two patients each relapsed three times, and were under biological surveillance for a long period (48 and 64 months respectively). In these two patients, the al AP fraction reappeared during each perceptible disease stage and disappeared during periods of remission. Autopsy performed for one of these patients did not reveal any liver involvement by Hodgkin's disease. evolution of the disease course for one of these patients.
Discussion
Diagnosis of liver involvement by Hodgkin's disease can only be proven by histology. Blind percutaneous biopsy detects only around 30% of such lesions. Multiple biopsies under laparoscopy or by laparotomy considerably improve detection rates (Bagley et al., 1973; De Vita et al., 1971; Glastein et al., 1969; MacLeod & Stalker, 1962 ). Hodgkin's lesions are generally diffuse from the outset, or at least multifocal (Wraight & Symmers 1966) . Such involvement is observed in 50% of patients who die as a direct result of Hodgkin's disease (Wraight & Symmers, 1966; Schener, 1973) .
However, the lesions oberved can be the source of debate, since even intense portal lymphocytic infiltration is insufficient for diagnosis (Bagley et al., 1973; Givler et al., 1971; Lukes, 1971) .
Histological examination is thus indispensable; a reliable, reproducible and non-traumatic method of evaluating hepatic involvement by Hodgkin's disease would also prove useful, especially during patient follow-up. Clinical examination to detect hepatomegaly (Bagley et al., 1973; Glastein et al., 1969; Givler et al., 1971) , liver scans (Givler et al., 1971) , ultrasonography (Caroll & Ta, 1980; Ginaldi et al., 1980) and CT all give numerous false positives or negatives. Biological tests such as the bilirubin concentration, BSP retention, gammaglutamyl transpeptidase, oxaloacetic or glutamatepyruvate transaminases, or 5-nucleotidase (which is useful in the case of malignant lymphomas) are not commonly employed (Belliveau et al., 1974; Deeble & Goldberg, 1980) . Alkaline phosphatases appear more useful: numerous studies have shown a clear correlation between the AP concentration and the disease stage (Belliveau et al., 1979; Deeble & Goldberg, 1980; Aisenberg et al., 1970; Kaplan, 1980) , whether or not there is any histologically proven liver involvement. The actual significance of elevation of AP levels remains unclear: an unexplained and occasionally intense liver retention syndrome has been observed for some time, disappearing in some cases after supradiaphragmatic radiotherapy of stage I or II disease (Perera et al., 1974) . Aisenberg et al. (1970) suggested that AP isoenzyme separation could be used to eliminate the false positives caused by the bone fraction in young patients in whom this fraction is physiologically elevated (Fishman & Ghosh, 1967 (Viot et al., 1979) . The origin of the Lxl AP fraction remains uncertain, although it appears to be the normal hepatic fraction associated with a lipoprotein complex which might be a fragment of a hepatocyte membrane (De Broe & Wieme, 1975; De Broe et al., 1975) . This would be compatible with the presence of an AP activity identical to al AP in bile (Viot et al., 1979) , the normal hepatocyte (Bagley et al., 1973; Viot et al., 1979; Aisenberg et al., 1970) , and neoplastic hepatocytes (Burlina & Buggiardini, 1978) .
The mechanism of appearance of the al AP fraction is serum also remains unclear. It is always present in cases of cytolysis or intense retention but may also be present on an isolated basis. In a previous study on the hepatic metastases of solid tumours, we found that al AP was a significantly more sensitive and often earlier biological indicator than total AP or yGT; furthermore, this test does not seem to be affected by the most common chemotherapy regimens (Viot et al., 1983) .
Significance of al AP during Hodgkin's disease In our series, the presence of al AP was correlated with the degree of disease extension (P<0.01) and with the presence of general signs (P<0.001). The al AP fraction did not appear to be directly linked to a specific liver pathology: it was found in the 3 patients with positive liver biopsies but was also detected in 7 patients in a perceptible disease stage, 5 of whom had an apparently normal liver parenchyma and 2 of whom presented nonspecific liver lesions (1 alcoholic hepatitis, 1 siderosis). However, the 5 patients with a normal liver parenchyma were investigated only by fine needle biopsy, which may have missed a Hodgkin's disease lesion.
al AP measurement versus total alkaline phosphatases In our series, the presence of al AP was correlated with an elevation of TAP (P<0.01) in patients in a perceptible disease stage (first stage or relapse); however, the value of al AP measurement appears particularly marked in instances where there is a discordance between these two parameters. Nine patients had a TAP level over 200IUl-1 without the al AP fraction, including 4 young patients (8, 9, 17, 19 years) and 2 elderly patients with an associated bone pathology for whom the bone fraction explained the high TAP level. al AP thus appears especially interesting for biological liver surveillance of children and young adults.
Conversely, for 13 of our patients, the al AP fraction was present although the TAP concentration was normal. One of these patients had Hodgkin's disease lesions of the liver, suggesting greater sensitivity for al AP measurements: this point warrants confirmation in a larger population. Two of these 13 patients had benign liver lesions. The remaining 10 patients in this group constitute a subgroup with a poor prognosis: they each had from 1 to 4 relapses, 3 died of their disease, and 3 have progressive disease.
A correlation thus exists with the disease course rather than with any specific hepatic pathology. For the patients followed up on a regular basis by monthly measurements in our study, the al AP fraction was observed to appear at the time of relapse. The al AP fraction does not seem to show up any earlier that the other biological markers available for the surveillance of Hodgkin's disease.
Conclusion
Measurement of the al AP fraction in the serum of 83 patients with Hodgkin's disease (59 at the time of initial staging, 22 at relapse, 12 during complete stable remission) revealed a statistically significant correlation with the degree of disease extension and the presence of general symptoms. During patient surveillance, the appearance and disappearance of this al AP fraction was closely linked with disease evolution. Measurement of this fraction seems to eliminate a certain number of the false positives and negatives encountered with TAP measurements.
